https://www.selleckchem.com/products/az-33.html
Nine N-IVIG lots manufactured between 2000 and 2018, derived from donors in Japan, were tested. Binding activity was evaluated by indirect immunofluorescence assay. None of the N-IVIG lots tested displayed neutralizing or binding activity against SARS-CoV-1, MERS-CoV, or SARS-CoV-2. However, they displayed substantial neutralizing and binding activity against HCoV OC43 and weak neutralizing and substantial binding activity against HCoV 229E. N-IVIG derived from healthy donors in Japan before the start of the COVID-19 pandemic had no direc
Curtir
Comentario
Compartilhar
